CStone Pharmaceuticals (HKG:2616) entered into a strategic commercial collaboration with UAE-based Pharmalink Store, a Thursday bourse filing said.

Under the license and commercialization agreement, Pharmalink will gain the commercial rights for tumor drug sugemalimab in the Middle East and North Africa (MENA) Region in return for upfront and regulatory milestone payments to CStone.

CStone Pharmaceuticals is responsible for the supply of the drug will also be entitled to royalties on the net sales of sugemalimab in the MENA Region and South Africa.